Antiretroviral Treatment for Adult HIV Infection in 2002

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

1998 • 9,382 citations

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

1998 • 4,297 citations

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 • 2,670 citations

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1998 • 2,421 citations

Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection

1997 • 2,097 citations

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1999 • 2,083 citations

Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

2002 • 1,355 citations

Adverse effects of antiretroviral therapy

2000 • 1,062 citations

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population

2000 • 1,050 citations

Antiretroviral Therapy in Adults

2000 • 1,045 citations

Immune control of HIV-1 after early treatment of acute infection

2000 • 1,012 citations

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

1999 • 1,008 citations

Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection

2000 • 971 citations

Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection

1999 • 960 citations

Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy

1998 • 861 citations

Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy

1999 • 824 citations

Mitochondrial toxicity of antiviral drugs

1995 • 760 citations

Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy

2001 • 739 citations

Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia

2001 • 657 citations

First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

1998 • 637 citations

Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus

1995 • 633 citations

Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors

1999 • 615 citations

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy

1999 • 607 citations

Antiretroviral Drug Resistance Testing in Adults With HIV Infection

1998 • 582 citations

“Buffalo hump” in men with HIV-1 infection

1998 • 581 citations

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

1998 • 555 citations

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

2000 • 542 citations

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors

1999 • 533 citations

U.S. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States

2002 • 528 citations

Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)

1995 • 524 citations

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy

2000 • 499 citations

Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection

2000 • 499 citations

Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary Study

1995 • 430 citations

Sex differences in HIV-1 viral load and progression to AIDS

1998 • 404 citations

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*

1998 • 402 citations

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects

2000 • 398 citations

Inflammatory Reactions in HIV-1–Infected Persons after Initiation of Highly Active Antiretroviral Therapy

2000 • 388 citations

Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy

2001 • 360 citations

Natural History of Human Immunodeficiency Virus Type 1 Viremia after Seroconversion and Proximal to AIDS in a Large Cohort of Homosexual Men

2000 • 355 citations

Metabolic effects of indinavir in healthy HIV-seronegative men

2001 • 352 citations

Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection

1999 • 348 citations

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

2000 • 332 citations

Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons.

1991 • 326 citations

Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy

1998 • 318 citations

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

2002 • 314 citations

The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients

1996 • 302 citations

Sustained CD4⁺T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus Infection

2000 • 299 citations

Tuberculosis in patients with the acquired immunodeficiency syndrome

1987 • 294 citations

HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load

2001 • 291 citations

Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response

1997 • 283 citations

Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>

2001 • 282 citations

Drug resistance mutations in HIV-1.

2004 • 282 citations

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1998 • 261 citations

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

2001 • 258 citations

Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy

2000 • 251 citations

Use of Changes in Plasma Levels of Human Immunodeficiency Virus Type 1 RNA to Assess the Clinical Benefit of Antiretroviral Therapy

1998 • 249 citations

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

2001 • 242 citations

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

1996 • 241 citations

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

1998 • 235 citations

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

2000 • 225 citations

A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1–Infected Patients

1998 • 221 citations

HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed

1999 • 219 citations

Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA

1999 • 214 citations

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection

2000 • 212 citations

Hyperlactatemia and Hepatic Abnormalities in 10 Human Immunodeficiency Virus-Infected Patients Receiving Nucleoside Analogue Combination Regimens

2000 • 210 citations

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

2000 • 209 citations

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

1999 • 199 citations

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

2002 • 198 citations

Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1_Mngp120, HIV‐1_SF2Recombinant gp120, or Both Vaccines in Seronegative Adults

1998 • 194 citations

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

2001 • 193 citations

Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy.

1995 • 193 citations

Predictors of optimal virological response to potent antiretroviral therapy

1999 • 185 citations

Increased β-Cell Secretory Capacity as Mechanism for Islet Adaptation to Nicotinic Acid-Induced Insulin Resistance

1989 • 181 citations

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

2001 • 181 citations

Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy

2000 • 179 citations

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters

2001 • 159 citations

Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients

2002 • 153 citations

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

2001 • 153 citations

Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).

1999 • 142 citations

A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection

1999 • 138 citations

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

2001 • 127 citations

Symptomatic Lactic Acidosis in Hospitalized Antiretroviral‐Treated Patients with Human Immunodeficiency Virus Infection: A Report of 12 Cases

2001 • 125 citations

CD4⁺T Cell Kinetics and Activation in Human Immunodeficiency Virus–Infected Patients Who Remain Viremic Despite Long‐Term Treatment with Protease Inhibitor–Based Therapy

2002 • 110 citations

Predictors of Long‐Term Increase in CD4⁺Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving a Protease Inhibitor–Containing Antiretroviral Regimen

2002 • 110 citations

Structured Treatment Interruptions for the Management of HIV Infection

2001 • 108 citations

Increase and Plateau of CD4 T-Cell Counts in the 3½ Years After Initiation of Potent Antiretroviral Therapy

2001 • 104 citations

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy

2000 • 101 citations

Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy

2001 • 96 citations

Osteonecrosis in Patients Infected with Human Immunodeficiency Virus: A Case‐Control Study

2001 • 96 citations

DRESS (Drug Rash with Eosinophilia and Systemic Syndrome Associated with Nevirapine Therapy

1998 • 94 citations

Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359

2000 • 92 citations

HIV and drug allergy

2001 • 91 citations

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population

2000 • 89 citations

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

2001 • 89 citations

ANTIVIRAL ACTIVITY OF TENOFOVIR (PMPA) AGAINST NUCLEOSIDE-RESISTANT CLINICAL HIV SAMPLES

2001 • 83 citations

Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection

1999 • 80 citations

The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements

1999 • 80 citations

HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort

2000 • 79 citations

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

2001 • 74 citations

Hypersensitivity Syndrome Associated with Efavirenz Therapy

2000 • 74 citations

Hyperlipidemia Associated with Protease Inhibitor Therapy

1999 • 73 citations

2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus July 2001: DRAFT

2001 • 68 citations

Predictors of Virologic and Clinical Outcomes in HIV-1–Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320

2001 • 67 citations

Bone Mineral Content Is Lower in Prepubertal HIV-Infected Children

2002 • 65 citations

Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients

2000 • 59 citations

The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load

2001 • 55 citations

Enhancing adherence to HAART: a pilot program of modified directly observed therapy.

2001 • 53 citations

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA

2000 • 51 citations

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

2001 • 51 citations

Competing drug–drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884

2000 • 47 citations

Alterations in Serum Levels of Lipids and Lipoproteins with Indinavir Therapy for Human Immunodeficiency Virus‐Infected Patients

1999 • 44 citations

HIV-1 Protease Inhibitors Induce an Increase of Triglyceride Level in HIV-Infected Men Without Modification of Insulin Sensitivity: A Longitudinal Study

2000 • 43 citations

Tenofovir, Adefovir, and Zidovudine Susceptibilities of Primary Human Immunodeficiency Virus Type 1 Isolates with Non-B Subtypes or Nucleoside Resistance

2001 • 43 citations

Both Serum HIV Type 1 RNA Levels and CD4⁺Lymphocyte Counts Predict Clinical Outcome in HIV Type 1-Infected Subjects with 200 to 500 CD4⁺Cells per Cubic Millimeter

2000 • 38 citations

Immunopathogenesis of human immunodeficiency virus.

1998 • 33 citations

A Randomized Study of the Utility of Human Immunodeficiency Virus RNA Measurement for the Management of Antiretroviral Therapy

2001 • 32 citations

Immunopathogenesis of Human Immunodeficiency Virus: Implications for Immune‐Based Therapies

2001 • 30 citations

Phenotypic Drug Susceptibility Testing Predicts Long‐Term Virologic Suppression Better than Treatment History in Patients with Human Immunodeficiency Virus Infection

2001 • 30 citations

A Longitudinal Analysis of Hospitalization and Emergency Department Use among Human Immunodeficiency Virus–Infected Women Reporting Protease Inhibitor Use

2001 • 29 citations

Comparison of T-Cell Subsets' Reconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease

2000 • 28 citations

[Antiretroviral therapy and immune reconstitution].

1999 • 27 citations

Effects of Tapering Doses of Oral Prednisone on Viral Load among HIV-Infected Patients with Unexplained Weight Loss

1997 • 27 citations

Abacavir Expanded Access Program for Adult Patients Infected with Human Immunodeficiency Virus Type 1

2002 • 24 citations

The Relationship between Virus Load Response to Highly Active Antiretroviral Therapy and Change in CD4 Cell Counts: A Report from the Women’s Interagency HIV Study

2000 • 21 citations

Structured treatment interruption.

2000 • 12 citations

Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.

1999 • 9 citations

Deleted Work

1955 • 0 citations